Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP issued a solicitation for investors to lead a securities fraud class action against Erasca, Inc. The complaint alleges that between January 2025 and April 2026, Erasca failed to disclose issues regarding preclinical data for ERAS-0015 and potential patent conflicts with RevMed.
Key figures
- Alleged drug
- ERAS-0015
- Class period end
- April 26, 2026
- Class period start
- January 14, 2025
- Lead plaintiff deadline
- August 10, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.